07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Flutiform fluticasone propionate/formoterol: Phase III data

Top-line data from the double-blind, international Phase III EFFECT trial in 1,767 COPD patients ages >=40 showed that twice-daily 250/10 ug inhaled flutiform for 52 weeks missed the primary endpoint of reducing annual rate of...
07:00 , Aug 30, 2016 |  BC Extra  |  Clinical News

Flutiform misses in COPD study

Vectura Group plc (LSE:VEC) said Flutiform fluticasone / formoterol missed the primary endpoint in a Phase III study to treat chronic obstructive pulmonary disease (COPD), and said partner Mundipharma International Ltd. (Cambridge, U.K.) will no...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

Fluticasone propionate/formoterol: Phase III data

A double-blind Phase III trial in 512 patients with asthma ages >=5 and <12 showed that twice-daily flutiform met the co-primary endpoints of superiority to fluticasone propionate (treatment difference of 0.07 L, p<0.001) and non-inferiority...
07:00 , May 5, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $3.51 (10%) to $32.39 on Friday after FDA asked for an additional clinical trial in a complete response letter for Plumiaz diazepam nasal spray to treat acute repetitive...
00:43 , Apr 30, 2014 |  BC Extra  |  Financial News

SkyePharma raises L112 million

SkyePharma plc (LSE:SKP) raised L112 million ($188.8 million) through the sale of 58.7 million shares at 191p in a placing and open offer. Shareholders were eligible to purchase 11 shares for every nine shares held...
07:00 , Apr 14, 2014 |  BioCentury  |  Finance

Debt riddance

Debt riddance SkyePharma plc (LSE:SKP) thinks it is worth giving away a pound of flesh to remove a debt overhang that was sucking up more than half of its free cash in recent years and...
23:42 , Mar 31, 2014 |  BC Extra  |  Financial News

SkyePharma to raise up to L112.1 million

Drug delivery company SkyePharma plc (LSE:SKP) proposed to raise up to L112.1 million ($186.5 million) through the sale of 58.7 million shares at 191p in a placing and open offer. The price is a 5%...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

SkyePharma, Mundipharma sales and marketing update

SkyePharma said Mundipharma launched flutiform fluticasone/formoterol in France to treat asthma. The launch triggered a €3 million ($4.1 million) milestone payment to SkyePharma from Mundipharma. The price for flutiform is €30.88 ($42.14) per inhaler for...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

SkyePharma, Kyorin sales and marketing update

Kyorin launched Flutiform fluticasone/formoterol in Japan to treat bronchial asthma. The Japanese National Health Insurance price for Flutiform is ¥2,735 ($27.35) per inhaler for the 50 µg fluticasone/5 µg formoterol dose and ¥2,193 ($21.93) per...